NT5E and lymphoma: All in all, studies on lymphoma are not recommended until breakthroughs occur.There are 19 clinical trials on CD73 on Clinicaltrials.gov, among which MEDI9447 (Oleclumab) is a human monoclonal antibody targeting CD73.